Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ventrus Announces Acquisition of Title to Hemorrhoids Product
NEW YORK , Nov. 18, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that on November 14, 2011 it completed its acquisition of all rights and title to VEN 309 (iferanserin) from the licensor, Sam Amer & Co. The total price paid for the asset was US$12.5 million
View HTML
Toggle Summary Ventrus Reports Third Quarter 2011 Financial Results
NEW YORK , Nov. 14, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) today reported financial results for the third quarter ended September 30, 2011 . In July, Ventrus received net cash proceeds of $47.5 million after closing a secondary public offering.
View HTML
Toggle Summary Ventrus Validates Large Patient Potential for VEN 309 With Survey Data From 10,000 Consumers
Expects to Deliver Top Line Results From Two Pivotal Trials in Mid-2012 and to Complete the Acquisition of the Global Rights and Title for VEN 309 From the Licensor
View HTML
Toggle Summary Ventrus BioSciences to Announce 3Q 2011 Financial Results, Clinical Update and Omnibus Market Research Results: Conference Call and Webcast
NEW YORK , Nov. 9, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it will report on its clinical trial progress, the initial topline results of a market research study commissioned by it and conducted by Princeton Biometrics on the U.S.
View HTML
Toggle Summary Ventrus Announces the Launch of the First Pivotal Trial of VEN 309 for the Treatment of Hemorrhoids
NEW YORK , Aug. 16, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that enrollment has opened at 65 of the 70 sites that will participate in the first pivotal Phase III trial of VEN 309 for the treatment of symptomatic hemorrhoids, and patients have now entered the
View HTML
Toggle Summary Ventrus Biosciences Announces Exercise of Underwriters' Over-Allotment Option and Closing of $51.75 Million Underwritten Registered Offering
NEW YORK , July 19, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced that it closed today its previously announced underwritten registered offering of 5,175,000
View HTML
Toggle Summary Ventrus Biosciences Announces Pricing of Its Underwritten Registered Offering of Common Stock
NEW YORK , July 14, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the pricing of its underwritten registered offering of 4,500,000 shares of its common stock at a price
View HTML
Toggle Summary Ventrus Receives SPA Response From FDA and Will Update and File the First Pivotal Trial Protocol to its IND
NEW YORK , June 22, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it has received a response from the U.S. Food and Drug Administration (FDA) to its last Special Protocol Assessment (SPA) submission for iferanserin (VEN 309) for the treatment of hemorrhoids,
View HTML
Toggle Summary Ventrus Receives Notice of Allowance for U.S. Patent for VEN 307
U.S. Patent Office Allows Claims for 2% Diltiazem Cream for Treatment of Anal Fissures
View HTML
Toggle Summary Ventrus Adds Third Treatment Arm of Shorter Treatment Duration to Its Phase III Study of Iferanserin in Hemorrhoids
NEW YORK , May 2, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it has added a third treatment arm to its first pivotal Phase III study of Iferanserin (VEN 309), the first prescription product candidate for the treatment of hemorrhoids.
View HTML